Novo Nordisk A/S Common Stock (NY:NVO)

Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility

September 26, 2025

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025....

Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick ↗

September 22, 2025

Via Stocktwits

Topics Intellectual Property

Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 26, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO

September 26, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Novo Nordisk A/S Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NVO

September 26, 2025

From DJS Law Group

Via Business Wire

Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs ↗

September 26, 2025

To gain an edge, this is what you need to know today.

Via Benzinga

NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Novo Nordisk Investors to Contact the Firm Before September 30th

September 26, 2025

From Bragar Eagel & Squire

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. ↗

September 26, 2025

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.

3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now ↗

September 26, 2025

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

Topics World Trade

September 25, 2025

Via Stocktwits

Topics Government

Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO

September 25, 2025

From Faruqi & Faruqi LLP

Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

Lost Money on Novo Nordisk A/S (NVO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 25, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Does This Acquisition Make Pfizer Stock a Great Buy? ↗

September 25, 2025

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025

Topics Death Intellectual Property

September 25, 2025

From Berger Montague

NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

September 25, 2025

From Bernstein Liebhard LLP

The latest data from the company's oral weight loss drug is bullish for the stock.

1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today ↗

September 25, 2025

The pharmaceutical leader is gradually laying the groundwork for a strong rebound.

Topics Economy

3 Reasons to Buy Novo Nordisk Stock Right Now ↗

September 25, 2025

NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th

September 24, 2025

From Bragar Eagel & Squire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

September 24, 2025

From Pomerantz LLP

Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset ↗

September 24, 2025

Via Benzinga

Topics ETFs

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO

September 23, 2025

From The Rosen Law Firm PA

Shares tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug ↗

September 23, 2025

Via Investor's Business Daily

Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape

September 22, 2025

As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating...

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Topics Artificial Intelligence Economy Intellectual Property

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Topics Economy Intellectual Property

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...